National Jewish Health, Denver, USA.
NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.
Adv Ther. 2020 Jul;37(7):3292-3298. doi: 10.1007/s12325-020-01380-4. Epub 2020 May 21.
Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited.
We used USA-based medical insurance claims (2014-2016) to assess use and cost of healthcare resources in PF-ILD. Patients with at least two ILD claims and at least one pulmonologist visit were considered to have ILD. Pulmonologist visit frequency was used as a proxy to identify PF-ILD (at least four visits in 2016, or at least three more visits in 2016 vs. 2014).
Of 2517 patients with non-IPF ILD, 15% (n = 373) had PF-ILD. Mean annual medical costs associated with ILD claims were $35,364 in patients with non-IPF PF-ILD versus $20,211 in the non-IPF ILD population. In 2016, patients with non-IPF PF-ILD made more hospital ILD claims than patients with non-IPF ILD (10.5 vs. 4.7).
These findings suggest higher disease severity and overall healthcare use for patients with a non-IPF ILD manifesting a progressive fibrosing phenotype (non-IPF PF-ILD).
特发性肺纤维化（IPF）是经典的进行性肺纤维化间质性肺疾病（ILD），但一些非 IPF 的ILD 患者也会发展为进行性肺纤维化表型（PF-ILD）。关于 PF-ILD 患者的医疗资源使用和成本信息有限。
我们使用美国医疗保险理赔数据（2014-2016 年）评估 PF-ILD 患者的医疗资源使用和成本。至少有两次ILD 理赔和至少一次肺科医生就诊的患者被认为患有ILD。肺科医生就诊频率被用作识别 PF-ILD 的指标（2016 年至少有四次就诊，或与 2014 年相比至少增加三次就诊）。
在 2517 名非 IPFILD 患者中，15%（n=373）患有 PF-ILD。与非 IPFILD 人群相比，PF-ILD 患者与ILD 理赔相关的年平均医疗费用为 35364 美元，而非 IPFILD 患者为 20211 美元。2016 年，PF-ILD 患者的ILD 住院理赔比非 IPFILD 患者更多（10.5 比 4.7）。
这些发现表明，表现出进行性纤维化表型的非 IPFILD（非 IPF PF-ILD）患者的疾病严重程度更高，整体医疗保健使用量更大。
